Kosin Medical Journal

Jihun Kang

2 Articles

Current understanding of modulated electro-hyperthermia in cancer treatment: Sungmin Kim, Jesang Yu, Jihun Kang, Yunkyung Kim, Taek Yong Ko; Kosin Med J. 2024;39(3):160-168. Published online September 23, 2024; DOI: https://doi.org/10.7180/kmj.24.127

529 View
21 Download

Abstract PDF PubReader ePub: Traditional hyperthermia involves increasing the temperature at the tumor site to above 39 ℃, inducing death in cancer cells. Although hyperthermia is an effective cancer treatment, its clinical application has decreased due to potential complications, including damage to surrounding normal tissue. In recent years, modulated electro-hyperthermia (mEHT) has emerged as an effective and safe treatment modality. mEHT selectively heats tumor cells to 42–43 °C, while reducing the average temperature in the treatment area, including the surrounding normal tissue, compared to conventional methods. Additionally, mEHT may be used in combination with systemic chemotherapy and radiation therapy in tumor treatment, providing a synergistic effect to increase efficacy. As chemotherapy and radiation therapy technologies advance, the application of combined mEHT may improve clinical outcomes. In this study, we review and discuss reports on the clinical outcomes of mEHT combined with chemotherapy and/or radiation therapy, which are established anticancer treatments.

The effects of ketamine on pain control in stage IV cancer patients receiving palliative care: Seonghoon Kim, Jihun Kang, Jongsoon Choi, Eunhee Kong; Kosin Med J. 2022;37(1):37-45. Published online March 14, 2022; DOI: https://doi.org/10.7180/kmj.21.003

3,460 View
86 Download
3 Citations

Background
We evaluated the effects of intravenous ketamine on cancer pain in stage IV cancer patients receiving palliative care.
Methods
In total, 253 stage IV cancer patients with cancer pain hospitalized at a single tertiary hospital palliative care unit were included. The ketamine group contained 112 patients receiving ketamine, and the control group comprised 141 non-ketamine users. To evaluate the odds ratios (ORs) for favorable pain control, optimal pain control, and opioid-sparing effect among ketamine users, we used multivariable logistic regression adjusted for age and objective prognosis score. Differences in the visual analog scale (VAS) score, oral morphine equivalents, inter-dose frequency, and inter-dose amount were compared between both groups at the time of ketamine introduction (T0), after 24 hours (T1), and after 48 hours (T2) using repeated-measures analysis of covariance.
Results
The ketamine group was more likely to show favorable pain control (OR, 3.84; 95% confidence interval [CI], 1.76–8.37) and an optimal response (OR, 3.99; 95% CI, 1.73–9.22) than the control group. Compared to the control group, the ketamine group showed a higher VAS score at T0, but a more evident VAS score reduction at T1 and T2 (pint<0.001). The ketamine group was less likely than the control group to experience depressive mood (OR, 0.31; 95% CI, 0.10–0.92), but had a higher risk of delirium (OR, 2.06; 95% CI, 1.12–3.91).
Conclusion
Our findings suggest that ketamine can effectively reduce refractory cancer pain in stage IV cancer patients.

Citations

Citations to this article as recorded by

Prevalence of Pain and Factors Affecting it in Patients with Lung Cancer in Ilam
Elham Bastani, Mahsa Rizehbandi, Fariba Shokri
International Journal of Cancer Management.2024;[Epub] CrossRef
A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial)
Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh, So Yeon Oh, Yun Jeong Hong, Seo-jun Kim, Eun-Ju Park, Nayeon Choi, Seon-Hi Shin, Sungeun Kim, Heejung Ko
American Journal of Hospice and Palliative Medicine®.2024;[Epub] CrossRef
Is ketamine useful for pain management in patients with stage IV cancer?
Sung Eun Kim
Kosin Medical Journal.2022; 37(1): 1. CrossRef

Author index